Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rocket Pharmaceuticals (RCKT) Capital Expenditures (2016 - 2025)

Rocket Pharmaceuticals' Capital Expenditures history spans 10 years, with the latest figure at -$360000.0 for Q4 2025.

  • For Q4 2025, Capital Expenditures fell 106.43% year-over-year to -$360000.0; the TTM value through Sep 2025 reached $6.0 million, up 21.27%, while the annual FY2024 figure was $5.9 million, 64.33% down from the prior year.
  • Capital Expenditures for Q4 2025 was -$360000.0 at Rocket Pharmaceuticals, down from $360000.0 in the prior quarter.
  • Across five years, Capital Expenditures topped out at $5.6 million in Q4 2024 and bottomed at -$3.7 million in Q3 2024.
  • The 5-year median for Capital Expenditures is $1.9 million (2022), against an average of $1.9 million.
  • The largest annual shift saw Capital Expenditures soared 4152.94% in 2021 before it crashed 179.48% in 2024.
  • A 5-year view of Capital Expenditures shows it stood at $2.0 million in 2021, then soared by 52.82% to $3.0 million in 2022, then skyrocketed by 54.75% to $4.6 million in 2023, then increased by 20.44% to $5.6 million in 2024, then crashed by 106.43% to -$360000.0 in 2025.
  • Per Business Quant, the three most recent readings for RCKT's Capital Expenditures are -$360000.0 (Q4 2025), $360000.0 (Q3 2025), and -$51000.0 (Q2 2025).